Nurexone Biologic Inc · TSXV:NRX
Nurexone Biologic — Investor Presentation (February 2023)
22 slides from Nurexone Biologic's investor presentation, February 2023
Slide 1: Regeneration. Rewiring. Recovery
REGENERATION. REWIRING. RECOVERY Investor Presentation Canada (TSXV: NRX) | Germany (J90)
Slide 2: Disclaimer
DISCLAIMER Contents of this presentation are provided for general information purposes only and do not constitute an offer to sell or solicitation of an offer to buy any security in any jurisdiction. This presentation contains “forward-looking information” for purposes of applicable securities laws
Slide 3: Snapshot
SNAPSHOT NurExone Biologic Inc. is a publicly-traded biopharmaceutical company, listed on the Toronto Corporate Stock Exchange and Frankfurt Stock Exchange. The company is developing and commercializing exosome-based therapies and a production platform for a global market projected at $5.2 billion I
Slide 4: Unleashing the Power of Exosomes
N U R EN XOUNREE. X CO NE.CO OM M UNLEASHING THE POWER OF EXOSOMES Introducing NurExone Biologic Inc. NurExone is an Israel-based biopharmaceutical company at the forefront of exosome-based therapeutics research and development, with a focus on revolutionizing recovery from Central Nervous System (C
Slide 5: Our Solution and First Product
N U R EN XOUNREE. X CO NE.CO OM M OUR SOLUTION AND FIRST PRODUCT Targeting Acute SCI One of the key assets of NurExone's technology is its drug delivery system, ExoTherapy. ExoPTEN, the first ExoTherapy product, which is designed to treat acute spinal cord injuries, has shown promising initial resul
Slide 6: ExoPTEN, Our First ExoTherapy Product
NUREXONE.COM ExoPTEN, OUR FIRST EXOTHERAPY PRODUCT Preclinical study results
Slide 7: NurExone at a Glance
NUREXONE AT A GLANCE
Slide 8: Invest in a Promising Future
N U R EN XOUNREE. X CO NE.CO OM M INVEST IN A PROMISING FUTURE Portfolio Company: One of the key assets of NurExone's technology is its proprietary therapeutic product, ExoPTEN targeting treatment of acute NurExone operates spinal cord injuries as the first indication,. It has a significant market a
Slide 9: Charting a Path to Success
N U R EN XOUNREE. X CO NE.CO OM M CHARTING A PATH TO SUCCESS Plans for commercialization, expansion, and collaboration • NurExone has obtained an exclusive worldwide license from the Technion and Tel Aviv University to develop and commercialize the exosome technology that has been under development
Slide 10: The Science Behind NurExone
THE SCIENCE ~ === BEHIND NUREXONE
Slide 11: Leveraging Exosomes to Create Our Solution and Product
N U R EN XOUNREE. X CO NE.CO OM M LEVERAGING EXOSOMES Exosomes, also known as extracellular vesicles, are nano-sized, naturally occurring particles in TO CREATE OUR SOLUTION the body, secreted by cells. AND PRODUCT Exosomes have a unique ability to ferry “cargo” to specific cells and inflamed tissue
Slide 12: Unlocking the Therapeutic Potential of Exosomes
N U R EN XOUNREE. X CO NE.CO OM M How does NurExone’s exosome-based UNLOCKING THE technology differ from other approaches being THERAPEUTIC used to treat acute Spinal Cord Injuries (SCI)? POTENTIAL OF EXOSOMES • Exosomes can be administered non-invasively, intranasally (through the nose) Advantages
Slide 13: Protecting Our Innovations
N U R EN XOUNREE. X CO NE.CO OM M PROTECTING OUR INNOVATIONS Learn about our U.S. Patent Application and the potential for future patents On January 13, 2023, NurExone received a notice of allowance from the United States Patent and Trademark Office (USPTO) for our U.S. Patent Application NO. 17/042
Slide 14: Clear Path Towards Clinical Trials
N U R EN XOUNREE. X CO NE.CO OM M CLEAR PATH TOWARDS CLINICAL TRIALS Plans for FDA and EMA Q4 2022 Q1 2023 H1 2023 Q3 2023 H2 2023 H1 2024 approval and the near future of clinical trials Filling new Establish scaled Finalize Opening in- In-Vivo IND submission patents up ExoPTEN product house scale e
Slide 15: Leadership Team
LEADERSHIP TEAM
Slide 16: Innovative Technology, Experienced Team
N U R EN XOUNREE. X CO NE.CO OM M INNOVATIVE Headquartered in Israel and incorporated in Canada the TECHNOLOGY, company is led by a team of world-renowned experts in the EXPERIENCED TEAM field of biotech and pharmaceuticals. An award-winning scientific team, The CEO is Dr. Lior Shaltiel and its Chai
Slide 17: Our Team
NUREXONE.COM OUR TEAM Lior Shaltiel, PhD Chief Executive Officer Business Development Finance Scientific Development Scientific Research Communications Yoram Drucker Eran Ovadya, Lyora Aharonov, Shulamit Inbar Paz Vice President MBA PhD Levenberg, PhD, Benayoun, LLB, Strategic Chief Financial Office
Slide 18: Scientific Advisory Board
NUREXONE.COM SCIENTIFIC SCIENTIFICADVISORY BOARD ADVISORY BOARD Prof. Gabriel Zeilig, MD Prof. Michael Belkin Prof. Shulamit Levenberg Prof. Daniel Offen Prof. Nahshon Knoller, MD Scientific Advisory Board Scientific Advisory Board Scientific Advisory Board Prof. Gabi Zeilig is the Prof. Belkin was
Slide 19: Directors
NUREXONE.COM DIRECTORS ISRAEL CANADA Ron Mayron Eyal Flom Dr. Lior Shaltiel Yoram Drucker Oded Orgil, LL.B. James (Jay) Director Director CEO Founder & VP Business Richardson Development Mr. Orgil has over 25 years Mr. Mayron held Mr. Flom has served as An entrepreneur and experience in Capital Mr.
Slide 20: Share Structure
TSXV: NRX | FSE: J90 Share Structure December 31, 2022 Common Shares 42,855,159 Warrants1 15,223,806 Options2 7,691,891 Fully Diluted Share Capital 65,770,856 1. Exercise Price: $1.20 CAD; expires between June 2023 and May 2024 2. Exercise Price: $0.80 CAD; expires between August 2031 and January 20
Slide 21: The Future Is Now
N U R EN XOUNREE. X CO NE.CO OM M THE FUTURE IS NOW • A cutting-edge biotech company focused on developing and commercializing innovative Join us on our mission to exosome-based therapeutics for spinal cord revolutionize recovery from injuries. nervous system injuries by regeneration and rewiring of
Slide 22: TSXV: NRX | FSE: J90
TSXV: NRX | FSE: J90 REGENERATION. REWIRING. RECOVERY Inbar Paz-Benayoun, Adv. Head of Communications and Investor Relations +972-52-3966695 info@nurexone.com NNUURREEXX O N NEE..CCOOMM
NurExone Biologic — Investor Presentation (February 2023) on 6ix